Posters

In 2 placebo-controlled studies of adults with attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release significantly reduced ADHD-Rating Scale IV total score (ADHD-RS-IV-TS) versus placebo. The current post hoc analyses examined SHP465 MAS treatment…

Objective: The study aims to determine the demographic predictors of attention-deficit/hyperactivity disorder (ADHD) in hospitalized children with autism spectrum disorder (ASD) and the impact of comorbidities on the length of stay (LOS).

College students are an at-risk population for prescription stimulant nonmedical use (NMU; use for any reason or in any way other than prescribed, including misuse/abuse). An online survey was used to study 3,011 respondents age 18-26 years: 1) college students involved in Greek life (fraternity/…

Attention-deficit/hyperactivity disorder (ADHD) treatment rates in adults are low, possibly owing to the discontinuation of care during the transition from adolescence to adulthood. To improve the understanding of treatment patterns during this transition, pharmacotherapy use was characterized in…

Background: AR19 is a pellets-in-capsule, immediate-release amphetamine sulfate investigational formulation with physical and chemical barriers designed to resist manipulation to deter snorting, smoking and intravenous injection. This was a randomized, double-blind, placebo-controlled, fixed-dose,…

Regulatory agencies and others have highlighted prescription ADHD stimulant medications as emerging drugs of misuse/abuse. College students, an especially high-risk group for stimulant misuse/abuse, were recruited via an online panel to complete a survey regarding nonmedical use (NMU; use for any…

Adult attention-deficit/hyperactivity disorder (ADHD) is associated with impaired executive function (EF). This post hoc analysis examines relationships between changes in ADHD symptoms and EF, as measured by the ADHD-Rating Scale-IV (ADHD-RS-IV) and Brown Attention-Deficit Disorder Scale (BADDS),…

Objective: Determine if AMPH EROS has an onset of effect at 30 minutes post-dose in children with ADHD.

Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into the evening. This pivotal, phase 3, forced-dose titration trial sought to determine whether DR/ER-MPH improves…

Adult attention-deficit/hyperactivity disorder (ADHD) can affect work productivity. This survey examined relationships between oral stimulant medication adherence, work productivity and related indirect costs, and ADHD symptom level among US adults diagnosed with ADHD.